vs
Criteo S.A.（CRTO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Criteo S.A.的1.6倍（$772.1M vs $482.7M），Revvity净利率更高（12.7% vs 4.4%，领先8.3%），Revvity同比增速更快（5.9% vs 2.4%），Revvity自由现金流更多（$161.8M vs $-36.6M），过去两年Revvity的营收复合增速更高（9.0% vs 1.4%）
Criteo S.A.是一家总部位于法国巴黎的广告服务商，专注于为客户提供在线展示广告服务，帮助品牌与媒体触达目标受众，是全球互联网广告领域的知名企业，深耕效果营销领域多年，服务众多跨境与本土客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CRTO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$482.7M
营收增速更快
RVTY
高出3.4%
2.4%
净利率更高
RVTY
高出8.3%
4.4%
自由现金流更多
RVTY
多$198.4M
$-36.6M
两年增速更快
RVTY
近两年复合增速
1.4%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $482.7M | $772.1M |
| 净利润 | $21.3M | $98.4M |
| 毛利率 | 53.6% | — |
| 营业利润率 | 6.3% | 14.5% |
| 净利率 | 4.4% | 12.7% |
| 营收同比 | 2.4% | 5.9% |
| 净利润同比 | -21.3% | 3.9% |
| 每股收益（稀释后） | $0.39 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRTORVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | $482.7M | $720.3M | ||
| Q1 25 | $451.4M | $664.8M | ||
| Q4 24 | $553.0M | $729.4M | ||
| Q3 24 | $458.9M | $684.0M | ||
| Q2 24 | $471.3M | $691.7M | ||
| Q1 24 | $450.1M | $649.9M |
净利润CRTORVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | $21.3M | $53.9M | ||
| Q1 25 | $37.9M | $42.2M | ||
| Q4 24 | $71.1M | $94.6M | ||
| Q3 24 | $6.2M | $94.4M | ||
| Q2 24 | $27.0M | $55.4M | ||
| Q1 24 | $7.2M | $26.0M |
毛利率CRTORVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | 53.6% | 54.5% | ||
| Q1 25 | 52.5% | 56.5% | ||
| Q4 24 | 54.4% | — | ||
| Q3 24 | 50.5% | 56.3% | ||
| Q2 24 | 49.4% | 55.7% | ||
| Q1 24 | 48.3% | 54.6% |
营业利润率CRTORVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 6.3% | 12.6% | ||
| Q1 25 | 10.7% | 10.9% | ||
| Q4 24 | 17.1% | 16.3% | ||
| Q3 24 | 2.1% | 14.3% | ||
| Q2 24 | 7.8% | 12.4% | ||
| Q1 24 | 2.3% | 6.8% |
净利率CRTORVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 4.4% | 7.5% | ||
| Q1 25 | 8.4% | 6.4% | ||
| Q4 24 | 12.9% | 13.0% | ||
| Q3 24 | 1.4% | 13.8% | ||
| Q2 24 | 5.7% | 8.0% | ||
| Q1 24 | 1.6% | 4.0% |
每股收益（稀释后）CRTORVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | $0.39 | $0.46 | ||
| Q1 25 | $0.66 | $0.35 | ||
| Q4 24 | $1.21 | $0.77 | ||
| Q3 24 | $0.11 | $0.77 | ||
| Q2 24 | $0.46 | $0.45 | ||
| Q1 24 | $0.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $223.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRTORVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | $223.6M | $991.8M | ||
| Q1 25 | $313.2M | $1.1B | ||
| Q4 24 | $316.9M | $1.2B | ||
| Q3 24 | $231.8M | $1.2B | ||
| Q2 24 | $233.2M | $2.0B | ||
| Q1 24 | $278.1M | $1.7B |
股东权益CRTORVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产CRTORVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-36.6M | $161.8M |
| 自由现金流率自由现金流/营收 | -7.6% | 21.0% |
| 资本支出强度资本支出/营收 | 7.3% | 2.6% |
| 现金转化率经营现金流/净利润 | -0.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRTORVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | $-1.4M | $134.3M | ||
| Q1 25 | $62.3M | $128.2M | ||
| Q4 24 | $169.5M | $174.2M | ||
| Q3 24 | $57.5M | $147.9M | ||
| Q2 24 | $17.2M | $158.6M | ||
| Q1 24 | $14.0M | $147.6M |
自由现金流CRTORVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $-36.6M | $115.5M | ||
| Q1 25 | $45.3M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | $-4.0M | $136.6M | ||
| Q1 24 | $173.0K | $129.7M |
自由现金流率CRTORVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | -7.6% | 16.0% | ||
| Q1 25 | 10.0% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | -0.9% | 19.7% | ||
| Q1 24 | 0.0% | 20.0% |
资本支出强度CRTORVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 7.3% | 2.6% | ||
| Q1 25 | 3.8% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | 4.5% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
现金转化率CRTORVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -0.07× | 2.49× | ||
| Q1 25 | 1.64× | 3.03× | ||
| Q4 24 | 2.38× | 1.84× | ||
| Q3 24 | 9.21× | 1.57× | ||
| Q2 24 | 0.64× | 2.87× | ||
| Q1 24 | 1.93× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRTO
| Commerce Growth | $393.9M | 82% |
| Retail Media | $60.9M | 13% |
| Other | $27.9M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
